Anti-Mouse RANKL (CD254) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse RANKL (CD254) – Purified in vivo GOLD™ Functional Grade
Product No.: R1352
Clone IK22/5 Target RANKL Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CD254, TRANCE, hRANKL2, sOdf, TNF-Related Activation-Induced Cytokine [TRANCE], Osteoprotegrin Ligan Isotype Rat IgG2a κ Applications B , FC , in vivo , IP , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Purified Recombinant Mouse RANKL (NSO-derived) Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2831709 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for RANKL antibody, clone IK22/5 for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl or 100 μl of whole blood. Titration of the reagent is recommended for optimal performance for each application. WB The suggested concentration for this RANKL antibody for use in western blotting is 1-10 μg/ml. Additional Applications Reported In Literature ? B IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone IK22/5 recognizes an epitope on mouse RANKL. Background RANKL antibody, clone IK22/5, recognizes receptor activator of NF-κB ligand (RANKL), also known as CD254, TNF-related activation-induced cytokine (TRANCE), tumor necrosis factor ligand superfamily member 11 (TNFSF11), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF). RANKL is a type II transmembrane protein belonging to the TNF cytokine superfamily and binds to the signaling receptor, RANK, or decoy receptor, osteoprotegerin (OPG). RANKL is expressed on osteoclasts and is essential for osteoclast differentiation, activation, and survival1. RANKL is also expressed on activated T cells and regulates T cell-dendritic cell (DC) interactions, enhancing DC activation and survival2-3. In addition, RANKL is crucial for lymph node, bone marrow, and thymus development4. Treatment with denosumab, an antibody directed against RANKL, is approved for the treatment of patients at high risk for bone fractures, including osteoporosis, and has shown anti-tumor effects5.
Antigen Distribution RANKL is expressed on activated T cells and osteoclasts. Ligand/Receptor RANK, OPG PubMed NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone IK22/5 is most commonly used in mice for in vivo functional blockade of RANKL (CD254), which is critical for studying the roles of RANKL in immune modulation and bone metabolism. Its primary in vivo application is the neutralization of RANKL signaling to assess the impact on osteoclast differentiation, bone resorption, T cell-dendritic cell interactions, and related pathologies. Key in vivo applications of IK22/5 in mice include:
Additional validated research applications of IK22/5 (some in vivo, some ex vivo/in vitro):
In summary, clone IK22/5 is widely used for in vivo neutralization of RANKL in mice, enabling the study of bone metabolism, immune function, and disease mechanisms where RANKL is implicated. Commonly used antibodies or proteins co-studied with IK22/5 (anti-mouse RANKL antibody) in the literature include:
Other relevant proteins sometimes included in IK22/5-based studies are biotinylated goat anti-rat IgG as a secondary reagent and markers/assays specific for osteoprotegerin, BMP2, or mineralization, depending on the research focus. In summary, the most frequent co-reagents are other immune checkpoint antibodies (PD-1, PD-L1, CTLA-4), RANK, B cell and T cell markers, and bone differentiation markers, reflecting the broad use of IK22/5 in both immunology and bone biology research. The key findings from scientific literature citing clone IK22/5—a monoclonal antibody targeting mouse RANKL (CD254/TRANCE)—focus on its role in bone metabolism, immunology, and cancer research:
Summary Table: Key Literature Findings on Clone IK22/5
Alternative Uses/Findings: Some studies attempt to use IK22/5 as a reference to compare new RANKL inhibitors or combination therapies, and it is included as a "gold standard" for functional antibody assays against RANKL. These findings establish clone IK22/5 as a foundational antibody for dissecting RANKL biology in murine systems and for preclinical therapeutic evaluation. Dosing regimens of clone IK22/5 (anti-mouse RANKL antibody) can vary significantly based on the mouse model, the experimental goal (e.g., blocking vs. detecting), and the application format (in vivo vs. flow cytometry vs. western blot): In vivo (functional blockade) dosing in mice:
In vitro/reagent-based applications:
Mouse strain considerations:
Summary Table:
Key points:
If a specific disease model or mouse strain is in question, refer to primary literature on that model for empirically validated regimens. References & Citations1. Park JH, et al. (2017) Mol Cells. 40(10):706-713 2. Wong BR, et al. (1997) J Biol Chem. 272(40):25190-4 3. Anderson, D. M., et al. (1997) Nature 390:175. 4. Ono T, et al. (2020) Inflamm Regen. 2020;40:2. 5. de Groot AF, at al. (2018) Cancer Treat Rev. 62:18-28 Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
